Paratek Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRTK research report →
About the company
Paratek Pharmaceuticals, Inc. , a biopharmaceutical firm headquartered in Boston, Massachusetts, and founded in 1996, is actively engaged in the commercialization of its products. The company's core mission involves the creation and market introduction of crucial medical treatments for severe illnesses or major public health crises, intended for civilian, governmental, and military applications.
- CEO
- Evan Loh FACC, FAHA,
- IPO
- 2009
- Employees
- 268
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $127.83M
- P/E
- -1.91
- P/S
- 0.85
- P/B
- -0.71
- EV/EBITDA
- -7.84
- Div Yield
- 0.00%
- Gross Margin
- 84.71%
- Op Margin
- -30.65%
- Net Margin
- -42.16%
- ROE
- 42.54%
- ROIC
- -34.19%
- Revenue
- $150.79M · 24.67%
- Net Income
- $-63,566,000 · -7.59%
- EPS
- $-1.17 · 4.10%
- Op Income
- $-46,209,000
- FCF YoY
- -36.04%
- 52W High
- $3.65
- 52W Low
- $1.29
- 50D MA
- $2.20
- 200D MA
- $2.06
- Beta
- 1.70
- Avg Volume
- 599.68K
Get TickerSpark's AI analysis on PRTK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 21, 23 | Baylor-Henry Minnie | sell | 32,800 |
| Sep 21, 23 | Baylor-Henry Minnie | sell | 12,800 |
| Sep 21, 23 | Baylor-Henry Minnie | sell | 26,400 |
| Sep 21, 23 | Hoffmann Rolf K | sell | 64,000 |
| Sep 21, 23 | Hoffmann Rolf K | sell | 7,000 |
| Sep 21, 23 | Hoffmann Rolf K | sell | 12,000 |
| Sep 21, 23 | Hoffmann Rolf K | sell | 5,000 |
| Sep 21, 23 | Hoffmann Rolf K | sell | 10,000 |
| Sep 21, 23 | Hoffmann Rolf K | sell | 20,000 |
| Sep 21, 23 | Hoffmann Rolf K | sell | 7,000 |
Our PRTK coverage
Recent articles, reports, and earnings notes.
No research on PRTK yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRTK report →Similar companies
Peers in the same neighborhood.